Table 2.
Univariate and multivariate analyses of Axl mRNA expression and other clinicopathological variables for patient survival
| Variables | Univariate analysis (OS) | Univariate analysis (DFS) | Multivariate analysis (OS) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Hazard ratio | 95 % CI | P* | Hazard ratio | 95 % CI | P* | Hazard ratio | 95 % CI | P † | |
| Axl mRNA expression | |||||||||
| Low | 1 | 0.047 | 1 | 0.094 | 1 | 0.04 | |||
| High | 2 | 1.01–4.8 | 1.7 | 0.91–3.5 | 1.9 | 1.03–3.5 | |||
| Age (yr) | |||||||||
| <65 | 1 | 0.47 | 1 | 0.75 | 1 | 0.2 | |||
| ≥65 | 0.77 | 0.38–1.6 | 0.91 | 0.5–1.7 | 0.71 | 0.43–1.2 | |||
| Gender | |||||||||
| Male | 1 | 0.0045 | 1 | 0.087 | 1 | 0.99 | |||
| Female | 0.3 | 0.17–0.73 | 0.57 | 0.32–1.08 | 1 | 0.43–2.1 | |||
| Smoking status | |||||||||
| Never smoked | 1 | 0.0026 | 1 | 0.051 | 1 | 0.37 | |||
| Smoker (ex or current) | 4.3 | 1.5–6.4 | 2 | 1–3.5 | 0.68 | 0.28–1.6 | |||
| Tumor differentiation | |||||||||
| Well | 1 | 1 | 1 | ||||||
| Moderately | 4.5 | 1.4–9.8 | 0.01 | 2.6 | 1.2–5.2 | 0.012 | 1.3 | 0.73–2.2 | 0.39 |
| Poorly | 11.8 | 5–38.7 | <0.001 | 4 | 2–11.8 | <0.001 | 3 | 1.4–6.4 | 0.004 |
| P-stage | |||||||||
| I | 1 | 1 | 1 | ||||||
| II | 0.55 | 0.12–3.1 | 0.56 | 1.3 | 0.41–4.6 | 0.6 | 0.63 | 0.22–1.5 | 0.33 |
| III | 5.9 | 4.6–26 | <0.001 | 5.3 | 5.3–26.7 | <0.001 | 2.1 | 1.1–4.1 | 0.022 |
| Adjuvant chemotherapy | |||||||||
| No | 1 | 1 | 1 | ||||||
| Yes | 0.51 | 0.2–1.04 | 0.061 | 0.62 | 0.29–1.2 | 0.14 | 0.45 | 0.25–0.8 | 0.0067 |
| EGFR gene mutation status | |||||||||
| Wild-type | 1 | 0.0077 | 1 | 0.29 | 1 | 1 | |||
| Mutation (+) | 0.35 | 0.19–0.77 | 0.72 | 0.39–1.3 | 1 | 0.54–1.9 | |||
| K-ras gene mutation status | |||||||||
| Wild-type | 1 | 0.23 | 1 | 0.12 | 1 | 0.63 | |||
| Mutation (+) | 0.49 | 0.23–1.4 | 0.46 | 0.25–1.2 | 1.2 | 0.55–2.6 | |||
Bold values are statistically significant
OS overall survival; DFS disease-free survival; CI confidence interval
* Log-rank test
†Cox’s proportional hazard model